182 related articles for article (PubMed ID: 27070719)
21. Calcitonin intranasal--unigene: Salcatonin intranasal--unigene.
Drugs R D; 2004; 5(2):90-3. PubMed ID: 15293868
[TBL] [Abstract][Full Text] [Related]
22. Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy.
Karsdal MA; Byrjalsen I; Henriksen K; Riis BJ; Christiansen C
Eur J Clin Pharmacol; 2010 Jan; 66(1):29-37. PubMed ID: 19813008
[TBL] [Abstract][Full Text] [Related]
23. Influence of food intake on the bioavailability and efficacy of oral calcitonin.
Karsdal MA; Byrjalsen I; Azria M; Arnold M; Choi L; Riis BJ; Christiansen C
Br J Clin Pharmacol; 2009 Apr; 67(4):413-20. PubMed ID: 19371314
[TBL] [Abstract][Full Text] [Related]
24. Prevention of osteoporosis with nasal salmon calcitonin: effect of anti-salmon calcitonin antibody formation.
Reginster JY; Gaspar S; Deroisy R; Zegels B; Franchimont P
Osteoporos Int; 1993 Sep; 3(5):261-4. PubMed ID: 8400608
[TBL] [Abstract][Full Text] [Related]
25. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss.
Gennari C; Agnusdei D; Montagnani M; Gonnelli S; Civitelli R
Calcif Tissue Int; 1992 Apr; 50(4):381-3. PubMed ID: 1571851
[TBL] [Abstract][Full Text] [Related]
26. Effect of nasal salmon calcitonin on calcium and bone metabolism.
Thamsborg G
Dan Med Bull; 1999 Apr; 46(2):118-26. PubMed ID: 10327295
[TBL] [Abstract][Full Text] [Related]
27. A pharmacokinetic and pharmacodynamic comparison of synthetic and recombinant oral salmon calcitonin.
Karsdal MA; Byrjalsen I; Henriksen K; Riis BJ; Christiansen C
J Clin Pharmacol; 2009 Feb; 49(2):229-34. PubMed ID: 19179298
[TBL] [Abstract][Full Text] [Related]
28. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Wensel TM; Iranikhah MM; Wilborn TW
Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
[TBL] [Abstract][Full Text] [Related]
29. Effects of continuous and cyclic nasal calcitonin administration in ovariectomized women.
Fioretti P; Gambacciani M; Taponeco F; Melis GB; Capelli N; Spinetti A
Maturitas; 1992 Dec; 15(3):225-32. PubMed ID: 1465036
[TBL] [Abstract][Full Text] [Related]
30. Preparation and Evaluation of Enteric-Coated Chitosan Derivative-Based Microparticles Loaded with Salmon Calcitonin as an Oral Delivery System.
Onishi H; Tokuyasu A
Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27649146
[TBL] [Abstract][Full Text] [Related]
31. Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers.
Nielsen NM; von der Recke P; Hansen MA; Overgaard K; Christiansen C
Calcif Tissue Int; 1994 Jul; 55(1):8-11. PubMed ID: 7922794
[TBL] [Abstract][Full Text] [Related]
32. Effect of different doses of nasal salmon calcitonin on bone mass.
Thamsborg G; Storm TL; Sykulski R; Brinch E; Nielsen HK; Sørensen OH
Calcif Tissue Int; 1991 May; 48(5):302-7. PubMed ID: 2054714
[TBL] [Abstract][Full Text] [Related]
33. Salmon calcitonin-loaded Eudragit® and Eudragit®-PLGA nanoparticles: in vitro and in vivo evaluation.
Cetin M; Aktas MS; Vural I; Ozturk M
J Microencapsul; 2012; 29(2):156-66. PubMed ID: 22126314
[TBL] [Abstract][Full Text] [Related]
34. [Postmenopausal osteoporosis treated with acupoint injection of salmon calcitonin:a randomized controlled trial].
Zhou Z; Wang N; Ding C; Zhou X; Zhou J
Zhongguo Zhen Jiu; 2016 Jul; 36(7):705-708. PubMed ID: 29231409
[TBL] [Abstract][Full Text] [Related]
35. [Effects of salmon calcitonin in treatment of osteoporosis in patients undergoing dialysis].
Wang SX; Li H
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(6):387-90. PubMed ID: 18581891
[TBL] [Abstract][Full Text] [Related]
36. Analgesic effect of intranasal and intramuscular salmon calcitonin in post-menopausal osteoporosis: a double-blind, double-placebo study.
Pontiroli AE; Pajetta E; Scaglia L; Rubinacci A; Resmini G; Arrigoni M; Pozza G
Aging (Milano); 1994 Dec; 6(6):459-63. PubMed ID: 7748920
[TBL] [Abstract][Full Text] [Related]
37. Mucoadhesive intestinal devices for oral delivery of salmon calcitonin.
Gupta V; Hwang BH; Lee J; Anselmo AC; Doshi N; Mitragotri S
J Control Release; 2013 Dec; 172(3):753-62. PubMed ID: 24035976
[TBL] [Abstract][Full Text] [Related]
38. Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials.
Karsdal MA; Byrjalsen I; Alexandersen P; Bihlet A; Andersen JR; Riis BJ; Bay-Jensen AC; Christiansen C;
Osteoarthritis Cartilage; 2015 Apr; 23(4):532-43. PubMed ID: 25582279
[TBL] [Abstract][Full Text] [Related]
39. Preventive treatment of cortical bone loss with salmon nasal calcitonin in early postmenopausal women.
Mango D; Ricci S; Manna P; Natili G; Dell'Acqua S
Minerva Endocrinol; 1993 Sep; 18(3):115-21. PubMed ID: 8183178
[TBL] [Abstract][Full Text] [Related]
40. PK/PD modelling of comb-shaped PEGylated salmon calcitonin conjugates of differing molecular weights.
Ryan SM; Frías JM; Wang X; Sayers CT; Haddleton DM; Brayden DJ
J Control Release; 2011 Jan; 149(2):126-32. PubMed ID: 20946924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
